Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) EVP Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $60.90, for a total value of $137,025.00. Following the completion of the transaction, the executive vice president directly owned 145,435 shares in the company, valued at approximately $8,856,991.50. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jim Wassil also recently made the following trade(s):
- On Monday, October 5th, Jim Wassil sold 18,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.74, for a total value of $1,561,320.00.
- On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.67, for a total value of $127,507.50.
- On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total transaction of $79,399.68.
- On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The stock was sold at an average price of $61.16, for a total transaction of $84,461.96.
- On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39.
Vaxcyte Trading Up 8.0%
NASDAQ:PCVX traded up $4.87 during trading hours on Wednesday, hitting $65.68. 2,257,729 shares of the company traded hands, compared to its average volume of 1,640,595. The stock has a market capitalization of $9.77 billion, a price-to-earnings ratio of -8.61 and a beta of 1.31. Vaxcyte, Inc. has a twelve month low of $39.87 and a twelve month high of $90.75. The firm has a 50-day moving average of $61.55 and a 200 day moving average of $57.07.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.12. Equities research analysts predict that Vaxcyte, Inc. will post -7.47 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Vaxcyte
Several institutional investors and hedge funds have recently bought and sold shares of PCVX. Jupiter Topco LLC bought a new position in shares of Vaxcyte during the 2nd quarter worth about $1,044,355,000. BlackRock Inc. acquired a new stake in shares of Vaxcyte during the 2nd quarter valued at about $701,520,000. Janus Henderson Group PLC increased its stake in Vaxcyte by 23.8% in the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after acquiring an additional 3,188,687 shares during the period. Wellington Management Group LLP increased its stake in Vaxcyte by 24.7% in the second quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock valued at $407,001,000 after acquiring an additional 1,386,968 shares during the period. Finally, Bank of America Corp DE bought a new stake in Vaxcyte in the second quarter valued at about $62,711,000. Institutional investors own 96.78% of the company’s stock.
Analyst Upgrades and Downgrades
PCVX has been the subject of several research reports. Needham & Company LLC increased their target price on shares of Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, October 2nd. Bank of America cut their price target on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a report on Monday, September 28th. Guggenheim raised their price objective on Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $120.00 price objective on shares of Vaxcyte in a report on Monday, October 12th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vaxcyte presently has an average rating of “Moderate Buy” and an average price target of $110.50.
View Our Latest Report on Vaxcyte
Vaxcyte Company Profile
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.
Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.
Featured Articles
- Five stocks we like better than Vaxcyte
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
